# Cure51

Source: https://onco.cc/companies/cure51/  
OnCo record `cure51` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Cure51 studies people who have lived for many years with cancers that usually progress quickly, such as glioblastoma and metastatic pancreatic cancer, to find what in their biology kept the cancer in check and turn it into new drug targets.

## Summary

Cure51 is a French computational biology company built around exceptional survivors: patients alive more than five years after a diagnosis of cancers such as metastatic pancreatic cancer, glioblastoma and small cell lung cancer. With a network of oncology centres that includes Gustave Roussy, Centre Léon Bérard, Charité, the European Institute of Oncology and Vall d'Hebron, it collects samples and clinical data from these survivors, looks for multimodal molecular signatures and builds a library of drug targets. Founded in March 2022 by Nicolas Wolikow and Simon Istolainen, it raised a EUR 15 million seed round in March 2024 led by Sofinnova Partners, with Hitachi Ventures, Life Extension Ventures, Xavier Niel and Olivier Pomel. In September 2026 it signed a long-term target identification partnership with Servier in glioblastoma.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- HQ: Paris
- Type: ai-software
- Website: https://www.cure51.com/

## Notes

- Founded in March 2022 per the company's seed release; included because its first announced financing was in 2024. The Servier deal value (the company cites up to EUR 442 million per target) is a ceiling of milestone payments, not money received, and was not checked against a Servier source.

## Sources

- Official website: https://www.cure51.com/
- Seed round press release, March 2024: https://prnewswire.co.uk/news-releases/cure51-raises-a-15-million-seed-round-to-harness-the-natural-power-of-cancer-survivors-and-contribute-to-cure-this-life-threatening-disease-302093663.html
- Company news: https://www.cure51.com/news

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- fronts: [AI & Computation](https://onco.cc/fronts/ai-computation/), [Drug Discovery Platforms](https://onco.cc/fronts/drug-discovery/)
- technologies: [AI-driven drug & target discovery](https://onco.cc/technologies/ai-drug-design/)
- companies: [Sofinnova Partners](https://onco.cc/companies/sofinnova-partners/)

---
JSON: https://onco.cc/api/v1/entities/cure51.json